Connostom completes financing HONG KONG , Jan. 13, 2025 PRNewswire- On January 13, Cornerstone Robotics, a representative of
China’s innovative surgical robot companies, announced the completion of a C round of financing of
over RMB 500 million. This round of financing was led by EQT, a large European private equity
investment firm, with participation from Qiming Venture Partners, Alpha JWC Ventures, Chuangke
Ventures, eGarden Ventures, Qingsong Capital, Xiangfeng K2VC, Meituan Longzhu and other
professional investment institutions at home and mauritania email list 100000 contact leads abroad. UBS Group served as the financial advisor
for this round of financing. The funds raised will help the company accelerate its commercialization
process, research and development of new surgical robot products, clinical trials, and global business development and cooperation.
This round of financing attracted support from several new strategic investors
Such as EQT and Alpha JWC Ventures. Among them, EQT Group is a Swedish private equity
investment company that manages funds ranked first in Europe and among the top three in the world.
The injection of top capital will provide upgrade of forms and interactions strong capital support for Connosten to expand its European
market. Alpha JWC Ventures, a leading venture capital firm in Southeast Asia, will play a key role in
helping Connosten further expand into the Southeast Asian market with its deep market insights and
rich investment experience. As an enterprise born in the Guangdong-Hong Kong-Macao Greater Bay
Area, the company has also received investment from the Innovation and Technology Venture Capital
Fund of the Innovation and Technology Commission
The Hong Kong Special Administrative Region Government. The support and participation of high-
quality investors is not only a recognition mobile lead of Connext’s innovation and globalization capabilities, but will
also help Connext reach greater heights on its journey toward globalization strategy.
Cornerstone Robotics adheres to the corporate mission of ” making surgery safe and broadening life ” , insists on independent innovation, and is committed to building a safe and efficient surgical robot platform. After five years of rapid and high-quality development Connostom completes financing.